CB1 inhibitor – Talk Bio

Actionable Insights Powered by AI

Skye Bioscience’s Nimacimab Fails Mid-Stage Obesity Trial, Stock Plummets

5 days ago talkbio0Tagged CB1 inhibitor, Clinical Setback, Nimacimab, Obesity Trial, Weight-Loss Agents

nimacimab; CB1 inhibitor; obesity trial; clinical setback; weight loss drug